Search

Author/Creator Johnson, Roderick Issue Volume 56(2023)

1. The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study. (February 2023)

Authors:
Ramchandren, Radhakrishnan; Johnson, Peter; Ghosh, Nilanjan; Ruan, Jia; Ardeshna, Kirit M.; Johnson, Roderick; Verhoef, Gregor; Cunningham, David; de Vos, Sven; Kassam, Shireen; Fayad, Luis; Radford, John; Bailly, Sarah; Offner, Fritz; Morgan, David; Munoz, Javier; Ping, Jerry; Szafer-Glusman, Ed...
Journal:
EClinicalMedicine
Issue:
Volume 56(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search